Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Assembly Biosciences Inc (ASMB)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Assembly Biosciences's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
13.695 +0.365    +2.74%
09:33:49 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 888
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 13.360 - 13.700
Assembly Biosciences 13.695 +0.365 +2.74%

NASDAQ:ASMB Financials

 
A brief overview of the NASDAQ:ASMB financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Ventrus over time.

Assembly Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 61.23 million compared to USD 93.09 million a year ago. Basic loss per share from continuing operations was USD 13.38 compared to USD 23.08 a year ago. Diluted loss per share from continuing operations was USD 13.38 compared to USD 23.08 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ASMB Income Statement

Gross margin TTM 70.46%
Operating margin TTM -902.5%
Net Profit margin TTM -854.78%
Return on Investment TTM -85.82%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 7.16
Gross Profit 42.94 -10.82 -12.52 -14.55
Operating Income -12.55 -15.05 -17.49 -19.56
Net Income -10.96 -14.42 -16.9 -18.95

ASMB Balance Sheet

Quick Ratio MRQ 3.32
Current Ratio MRQ 3.41
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 5.7%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 136.82 51.63 66.58 83.12
Total Liabilities 95.73 9.92 11.63 12.78
Total Equity 41.1 41.71 54.95 70.33

ASMB Cash Flow Statement

Cash Flow/Share TTM 4.15
Revenue/Share TTM 1.31
Operating Cash Flow  187.79%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 73.65 -13.85 -13.63 -23.43
Cash From Investing Activities -89.65 18.88 -8.36 10
Cash From Financing Activities 9.19 0 0.134 4.49
Net Change in Cash -6.82 5.03 -21.86 -8.94
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ASMB Comments

Write your thoughts about Assembly Biosciences Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ferenc Pallag
Ferenc Pallag Feb 28, 2022 8:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it's under their cash balance...
Reply
0 1
Report
Alberto Casserà
Alberto Casserà Feb 24, 2022 11:34AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Woke up?
Reply
0 0
Report
Ferenc Pallag
Ferenc Pallag Dec 15, 2021 12:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
looks like, there's an issue here...
Reply
0 0
Report
Ferenc Pallag
Ferenc Pallag May 06, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
?
Reply
0 0
Report
Tzvetan Petiov
Tzvetan Petiov May 05, 2021 3:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Si sube bien y si baja ps mejor todavi porque recompro
Reply
1 0
Report
Alberto Casserà
Alberto Casserà Apr 19, 2021 12:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
New good position 4.10 🚀
Reply
0 1
Report
Alberto Casserà
Alberto Casserà Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I’m in now. I believe it! 💪🏼
Reply
3 0
Report
Ferenc Pallag
Ferenc Pallag Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hope, you've enough time to wait for the profit:)
Reply
0 0
Report
Alberto Casserà
Alberto Casserà Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ferenc Pallag time is basic
Reply
0 0
Report
Ferenc Pallag
Ferenc Pallag Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Alberto Casserà Sure...no further, than 2023
Reply
0 0
Report
Alberto Casserà
Alberto Casserà Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
300-400% during 2-3 years is not bad...patience and divresification are strength...mistakes also...we’ll see whats going on :)
Reply
0 0
Report
Ferenc Pallag
Ferenc Pallag Mar 04, 2021 10:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
well said, however 10-15x is possible here with a successful cure approval...Arbutus technology is the key. If that's not help, then nothing...
Reply
0 0
Report
Ferenc Pallag
Ferenc Pallag Mar 03, 2021 1:56PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Long and bumpy road ahead...best case is a Phase 2 approval for this year.
Reply
0 0
Report
Alberto Casserà
Alberto Casserà Mar 03, 2021 12:43PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Any rumors? Who’s in?
Reply
0 0
Report
Ab High
Ab High Nov 06, 2020 10:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what happened
Reply
3 0
Report
Ricardo Grande
Ricardo Grande Nov 06, 2020 10:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
HBV trial failed.
Reply
3 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email